Coronaviridae · Alphacoronavirus
| Alisporivir | HCoV-229E | — | Preclinical | — | Human CYPs | |
| Apilimod | HCoV-229E | PIKfyve kinase inhibitor | Preclinical | — | Human PTK | |
| Boceprevir | HCoV-229E | NS3/4a protease inhibitor | Preclinical | — | Viral protease | |
| Chlorpromazine | HCoV-229E | Inhibits assembly of clathrin-coated pits at the plasma membrane | Preclinical | — | Human (multiple) | |
| CR-1-31-B | HCoV-229E | Prevents mRNA translation | Preclinical | — | Human ATPase | |
| Cyclosporine | HCoV-229E | Calcineurin inhibitor; allows for inhibition of T cell activation | Preclinical | — | Human CYPs | |
| Formoterol | HCoV-229E | Long-acting selective ?2-adrenergic receptor agonist | Preclinical | — | Unknown | |
| Nafamostat | HCoV-229E | Synthetic serine protease inhibitor | Preclinical | — | Human protease | |
| Raloxifene | HCoV-229E | Selective estrogen receptor modulator | Preclinical | — | Human (multiple) | |
| Remdesivir | HCoV-229E | Viral RNA polymerase inhibitor | Approved (other) | Japan | Viral RNA pol | |
| Silvestrol | HCoV-229E | RNA helicase inhibitor | Preclinical | — | Human EIF4A | |
| Tamoxifen | HCoV-229E | Estrogen receptor antagonist | Preclinical | — | Human (multiple) | |
| Tetrandine | HCoV-229E | Prevents viral entry | Preclinical | — | Human ion channel | |
| Umifenovir | HCoV-229E | Inhibits membrane fusion | Preclinical | — | Human (multiple) | |
| Verapamil | HCoV-229E | Voltage-dependent calcium channels inhibitor | Preclinical | — | Human ion channel |